US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPUS GENETICS INC

1.01

+0.01001.00%

Volume:185.71K

Turnover:188.12K

Market Cap:60.26M

PE:-0.50

High:1.03

Open:1.00

Low:0.9815

Close:1.00

Loading ...

Overview Company News Filings

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Opus Genetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Opus Genetics Says Presbyopia Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial

MT Newswires Live

BRIEF-Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint For Phentolamine Ophthalmic Solution

Opus Genetics Inc - Vega-3 Trial Meets Key Secondary Efficacy Endpoints

THOMSON REUTERS

Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

THOMSON REUTERS

BRIEF-Opus Genetics Says Nirav Jhaveri Departs As CFO - SEC Filing

Opus Genetics Inc - Nirav Jhaveri Departs as CFO of Opus Genetics - SEC Filing

THOMSON REUTERS

Opus Genetics Inc - Amy Rabourn to Serve as Interim CFO and Principal Accounting Officer - SEC Filing

THOMSON REUTERS

Opus Genetics Inc. Announces Departure of CFO Nirav Jhaveri; Amy Rabourn Appointed Interim Financial Officer

BRIEF-Opus Genetics Inc - Secures Up To $2 Million Funding From RD Fund

Opus Genetics Inc - Expects Cash to Fund Operations Into Second Half of 2026

THOMSON REUTERS

Opus Genetics Inc - Secures up to $2 Mln Funding From Rd Fund

THOMSON REUTERS

Press Release: Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Inc. Secures $2 Million Funding from Foundation Fighting Blindness Retinal Degeneration Fund to Advance Gene Therapy Program for Retinitis Pigmentosa

Opus Genetics Initiated at Buy by LUCID CAPITAL MARKETS

Opus Genetics initiated with a Buy at Lucid Capital

Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment

Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

Opus Genetics Inc. Reports Positive Q1 2025 Results with Encouraging OPGx-LCA5 Trial Data and $21.5M Fundraising

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IRD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":1.01,"timestamp":1751915465498,"preClose":1,"halted":0,"volume":185708,"delay":0,"floatShares":52711500,"shares":59661197,"eps":-2.017439,"marketStatus":"Trading","change":0.01,"latestTime":"07-07 15:11:06 EDT","open":1,"high":1.03,"low":0.9815,"amount":188118.22984880002,"amplitude":0.0485,"askPrice":1.03,"askSize":1230,"bidPrice":1.01,"bidSize":738,"shortable":3,"etf":0,"ttmEps":-2.017439,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751918400000},"marketStatusCode":2,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":1.01,"preClose":1,"latestTime":"09:22 EDT","volume":3937,"amount":3868.9099787,"timestamp":1751894530518},"postHourTrading":{"tag":"盘后","latestPrice":0.9801,"preClose":1,"latestTime":"16:47 EDT","volume":4086,"amount":4059.5359,"timestamp":1751575633704},"volumeRatio":0.568941,"impliedVol":0.6854,"impliedVolPercentile":0.6705},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":52711500,"roa":"-45.36%","roe":"-167.55%","lyrEps":-2.153504,"volumeRatio":0.568941,"shares":59661197,"dividePrice":0,"high":1.03,"amplitude":0.0485,"preClose":1,"low":0.9815,"week52Low":0.65,"pbRate":"11.88","psRate":"4.41","week52High":2.18,"institutionHeld":0,"latestPrice":1.01,"committee":-0.25,"eps":-2.017439,"divideRate":0,"volume":185708,"delay":0,"ttmEps":-2.017439,"open":1,"prevYearClose":1.19,"prevWeekClose":1,"prevMonthClose":0.9421,"prevQuarterClose":0.9421,"fiveDayClose":0.9766,"twentyDayClose":1,"sixtyDayClose":0.7487},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548387946","title":"Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2548387946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548387946?lang=en_us&edition=fundamental","pubTime":"2025-07-04 04:30","pubTimestamp":1751574600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nTUA7WY0DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2546126710","title":"Opus Genetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2546126710","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546126710?lang=en_us&edition=fundamental","pubTime":"2025-06-27 19:11","pubTimestamp":1751022660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 27, 2025 07:11 ET (11:11 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2546787928","title":"Opus Genetics Says Presbyopia Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787928","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546787928?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:42","pubTimestamp":1750938172,"startTime":"0","endTime":"0","summary":"Opus Genetics  said Thursday that its second pivotal phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia met its primary endpoint.The randomized, double-masked, placebo-controlled study enrolled 545 participants across 40 US sites. Patients received either the treatment or a placebo once daily in the evening. The results showed that 27.2% of patients achieved a 15-letter or more improvement in near visual acuity without significant loss in distance vision, compared with 11.5% in the placebo group.The trial also met its secondary endpoints, with no serious adverse events or signs of tachyphylaxis over six weeks. The safety profile was consistent with earlier studies, the company said.Opus CEO George Magrath said the company plans to file an application with the FDA in the second half of the year.Opus Genetics shares were up over 11% in recent premarket activity on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD","BK4007","IRD.AU","BK4139","BK7129"],"gpt_icon":0},{"id":"2546685784","title":"BRIEF-Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint For Phentolamine Ophthalmic Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2546685784","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546685784?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:57","pubTimestamp":1750935462,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint For Phentolamine Ophthalmic SolutionJune 26 (Reuters) - Opus Genetics Inc IRD.O:OPUS GENETICS ANNOUNCES VEGA-3 PHASE 3 TRIAL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA8SVDQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2546784566","title":"Opus Genetics Inc - Vega-3 Trial Meets Key Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2546784566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546784566?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:55","pubTimestamp":1750935300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA8SVDQD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2546784554","title":"Opus Genetics Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia","url":"https://stock-news.laohu8.com/highlight/detail?id=2546784554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546784554?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:55","pubTimestamp":1750935300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA8SVDQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2546229536","title":"BRIEF-Opus Genetics Says Nirav Jhaveri Departs As CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2546229536","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546229536?lang=en_us&edition=fundamental","pubTime":"2025-06-26 05:26","pubTimestamp":1750886810,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics Says Nirav Jhaveri Departs As CFO - SEC FilingJune 25  - Opus Genetics Inc IRD.O:OPUS GENETICS INC - NIRAV JHAVERI DEPARTS AS CFO OF OPUS GENETICS - SEC FILINGOPUS GENETICS INC - AMY RABOURN TO SERVE AS INTERIM CFO AND PRINCIPAL ACCOUNTING OFFICER - SEC FILINGSource text: [ID:n0001140361-25-023648]Further company coverage: IRD.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS0Q0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2546259732","title":"Opus Genetics Inc - Nirav Jhaveri Departs as CFO of Opus Genetics - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2546259732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546259732?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:23","pubTimestamp":1750883033,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS0Q0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2546225978","title":"Opus Genetics Inc - Amy Rabourn to Serve as Interim CFO and Principal Accounting Officer - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2546225978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546225978?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:23","pubTimestamp":1750883033,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS0Q0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2546922597","title":"Opus Genetics Inc. Announces Departure of CFO Nirav Jhaveri; Amy Rabourn Appointed Interim Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2546922597","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546922597?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:23","pubTimestamp":1750882997,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has announced a management change with the departure of Chief Financial Officer Nirav Jhaveri. Amy Rabourn, currently the Senior Vice President of Finance, will serve as the interim principal financial officer and principal accounting officer until a successor is appointed. Rabourn, who has over 20 years of finance and accounting experience, joined Opus Genetics in November 2020 and was promoted to her current role in January 2023.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2025, and is sole","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL6RjjCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2545411884","title":"BRIEF-Opus Genetics Inc - Secures Up To $2 Million Funding From RD Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2545411884","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545411884?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:03","pubTimestamp":1750680226,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics Inc - Secures Up To $2 Million Funding From RD FundJune 23 (Reuters) - Opus Genetics Inc IRD.O:OPUS GENETICS INC - SECURES UP TO $2 MILLION FUNDING FROM RD FUNDOPUS GENETICS INC - ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nFWN3SO05J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2545419709","title":"Opus Genetics Inc - Expects Cash to Fund Operations Into Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419709?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680049,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nFWN3SO05J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2545083419","title":"Opus Genetics Inc - Secures up to $2 Mln Funding From Rd Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2545083419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545083419?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nFWN3SO05J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"gpt_icon":0},{"id":"2545419232","title":"Press Release: Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419232?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680000,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., June 23, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases  and small molecule therapies for other ophthalmic disorders, recently disclosed that the Retinal Degeneration Fund , the venture philanthropy arm of the Foundation Fighting Blindness, has entered into a funding agreement with Opus providing for up to $2 million in non-dilutive funding intended to support the advancement of Opus' OPGx-MERTK program to develop gene therapies to treat patients impacted by retinitis pigmentosa caused by pathogenic variants in the Mer proto-oncogene tyrosine kinase  gene.\"This strategic funding enables us to advance the development of OPGx-MERTK, a promising program that aims to address a retinal degenerative condition with no currently approved therapies,\" said George Magrath, M.D., CEO, Opus Genetics. \"OPGx-MERTK is currently in preclinical development, and we","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2545170421","title":"Opus Genetics Inc. Secures $2 Million Funding from Foundation Fighting Blindness Retinal Degeneration Fund to Advance Gene Therapy Program for Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170421","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170421?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:12","pubTimestamp":1750450351,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. Secures $2 Million Funding from Foundation Fighting Blindness Retinal Degeneration Fund to Advance Gene Therapy Program for Retinitis Pigmentosa. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLxLbyM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2544999684","title":"Opus Genetics Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2544999684","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544999684?lang=en_us&edition=fundamental","pubTime":"2025-06-17 23:38","pubTimestamp":1750174680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2025 11:38 ET (15:38 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4007","BK4596","LCID","IRD","BK4555","BK4139","BK4551"],"gpt_icon":0},{"id":"2544396974","title":"Opus Genetics initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2544396974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544396974?lang=en_us&edition=fundamental","pubTime":"2025-06-17 18:45","pubTimestamp":1750157115,"startTime":"0","endTime":"0","summary":"Lucid Capital analyst Dev Prasad initiated coverage of Opus Genetics (IRD) with a Buy rating and $5 price target The company’s lead program, OPGx-L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4099","BK4551","BK4139","BK4007","BK4555","BK4596","IRD","LCID"],"gpt_icon":0},{"id":"2540979139","title":"Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540979139","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540979139?lang=en_us&edition=fundamental","pubTime":"2025-06-02 22:51","pubTimestamp":1748875860,"startTime":"0","endTime":"0","summary":"Opus Genetics shares were up 22% at $1.21, after the company said it saw positive topline results from a pivotal Phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of chronic night driving impairment in keratorefractive patients with reduced mesopic vision.The biopharmaceutical company said the treatment is meant to help patients who undergo keratorefractive eye procedures, such as laser-assisted in situ keratomileusis.The study met its primary endpoint of a gain of three lines--or 15 letters--or more of distance vision improvement on a low-contrast chart in low light conditions after 15 days of dosing.Opus said the study showed a safety profile consistent with previous studies, with no new safety signals identified. No evidence of tachyphylaxis was observed in this study over the six-week period.The stock hit its 52-week low of 65 cents on April 10, and is down 27% in the past 12 months.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2535802354","title":"Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535802354","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535802354?lang=en_us&edition=fundamental","pubTime":"2025-05-16 16:12","pubTimestamp":1747383170,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc reports results for the quarter ended March 31 - Earnings SummaryOpus Genetics Inc IRD.OQ reported a quarterly adjusted loss of 24 cents per share for the quarter ended March 31, hig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL8N3RO0FL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2535477828","title":"Opus Genetics Inc. Reports Positive Q1 2025 Results with Encouraging OPGx-LCA5 Trial Data and $21.5M Fundraising","url":"https://stock-news.laohu8.com/highlight/detail?id=2535477828","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535477828?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:28","pubTimestamp":1747312122,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL7Pbrky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":84,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"IRD","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-08-13","symbol":"IRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":-0.3},{"market":"US","date":"2024-05-10","symbol":"IRD","fiscalQuarterEnding":"2024/03","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744430400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2025-07-03","current":-1.017762,"percent":0.636905,"low":-2.964142,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"high":-0.560128,"avg":-1.201126,"sd":0.479614,"marketCap":59661197},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197}],"updateTime":1751887016939}}}